Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q3 2025

Holdings as of Sep 30, 2025, filed Nov 13, 2025. Long positions only; changes compare share counts with Q2 2025.

Institution overview
Positions
86
+9 vs. Q2 2025
Portfolio value
$1.07B
+$398.5M (+58.9%) vs. Q2 2025
Filed
Nov 13, 2025
SEC
Holdings of Affinity Asset Advisors, LLC in Q3 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$2.99K<0.1%00.0%Unchanged–
SPRYARS Pharmaceuticals, Inc.COM2,500$25.1K<0.1%+2,500NewHistory
QTTBQ32 Bio Inc.COM27,777$55.0K<0.1%00.0%UnchangedHistory
ADGMAdagio Medical Holdings, Inc.COM80,000$155.2K<0.1%00.0%UnchangedHistory
CBIOCrescent Biopharma, Inc.COM17,998$214.0K<0.1%−262,033−93.6%ReducedHistory
RPTXRepare Therapeutics Inc.COM200,000$352.0K<0.1%00.0%UnchangedHistory
CNTXContext Therapeutics Inc.COM402,653$390.1K<0.1%−115,372−22.3%ReducedHistory
ENGNenGene Therapeutics Inc.COM77,000$525.9K<0.1%00.0%UnchangedHistory
JBIOJade Biosciences, Inc.COM NEW65,317$563.7K0.1%00.0%UnchangedHistory
STROSutro Biopharma, Inc.COM752,722$653.7K0.1%00.0%UnchangedHistory
CATXPerspective Therapeutics, Inc.COM NEW300,000$1.03M0.1%−750,000−71.4%ReducedHistory
NXTCNextCure, Inc.COM NEW191,882$1.12M0.1%00.0%UnchangedConverted for a 1-for-12 splitHistory
CMPSCOMPASS Pathways plcSPONSORED ADS200,000$1.15M0.1%+200,000NewHistory
MISTMilestone Pharmaceuticals Inc.COM666,666$1.33M0.1%+666,666NewHistory
CGEMCullinan Therapeutics, Inc.COM263,817$1.56M0.1%00.0%UnchangedHistory
EPRXEupraxia Pharmaceuticals Inc.COM300,000$1.77M0.2%+300,000NewHistory
OBIOOrchestra BioMed Holdings, Inc.COM727,272$1.80M0.2%+727,272NewHistory
AVRAnteris Technologies Global Corp.COM450,000$2.02M0.2%+25,000+5.9%AddedHistory
GERNGeron CorpCOM1,500,000$2.06M0.2%00.0%UnchangedHistory
UTHRUnited Therapeutics CorpCOM5,000$2.10M0.2%+5,000NewHistory
ATXSAstria Therapeutics, Inc.COM300,000$2.18M0.2%00.0%UnchangedHistory
SGMTSagimet Biosciences Inc.COM SER A350,000$2.40M0.2%+350,000NewHistory
OLMAOlema Pharmaceuticals, Inc.COM250,000$2.45M0.2%00.0%UnchangedHistory
CLYMClimb Bio, Inc.COM1,300,000$2.61M0.2%−200,000−13.3%ReducedHistory
OACCUOaktree Acquisition Corp. III Life SciencesUNIT 10/04/2029250,000$2.66M0.2%00.0%UnchangedHistory
OCULOcular Therapeutix, IncCOM239,000$2.79M0.3%+239,000NewHistory
AUTLAutolus Therapeutics plcSPON ADS1,750,000$2.85M0.3%−1,295,000−42.5%ReducedHistory
MBXMBX Biosciences, Inc.COM165,000$2.89M0.3%+165,000NewHistory
CRNXCrinetics Pharmaceuticals, Inc.COM75,000$3.12M0.3%−77,252−50.7%ReducedHistory
JAZZJazz Pharmaceuticals plcSHS USD25,000$3.29M0.3%00.0%UnchangedHistory
BBIOBridgeBio Pharma, Inc.COM65,000$3.38M0.3%−85,000−56.7%ReducedHistory
OVIDOvid Therapeutics Inc.COM2,650,000$3.44M0.3%+1,982,484+297.0%AddedHistory
INSPInspire Medical Systems, Inc.COM50,000$3.71M0.3%+50,000NewHistory
FRNMFreenome, Inc.CL A ORD SHS350,000$3.76M0.3%00.0%UnchangedHistory
Celcuity Inc.15102KAA8NOTE 2.750% 8/0–$4.00M0.4%–New–
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202245,000$4.19M0.4%00.0%UnchangedHistory
PCVXVaxcyte, Inc.COM125,000$4.50M0.4%00.0%UnchangedHistory
RVMDRevolution Medicines, Inc.COM100,000$4.67M0.4%+100,000NewHistory
Omeros Corp682143AK8NOTE 9.500% 6/1–$4.71M0.4%–––
IMVTImmunovant, Inc.COM300,000$4.84M0.4%+300,000NewHistory
SVRASavara IncCOM1,500,000$5.36M0.5%+1,000,000+200.0%AddedHistory
VRDNViridian Therapeutics, Inc.COM250,000$5.39M0.5%−140,000−35.9%ReducedHistory
ZURAZura Bio LtdCLASS A ORD SHS1,274,351$5.52M0.5%+1,051,016+470.6%AddedHistory
MNPRMonopar TherapeuticsCOM NEW79,483$6.49M0.6%+11,983+17.8%AddedHistory
AKBAAkebia Therapeutics, Inc.COM2,450,000$6.69M0.6%+500,000+25.6%AddedHistory
TARSTarsus Pharmaceuticals, Inc.COM125,000$7.43M0.7%+125,000NewHistory
PRQRProQR Therapeutics N.V.SHS EURO3,600,000$7.67M0.7%+100,488+2.9%AddedHistory
CLDXCelldex Therapeutics, Inc.COM NEW300,000$7.76M0.7%+300,000NewHistory
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES275,000$7.82M0.7%00.0%UnchangedHistory
Travere Therapeutics, Inc.89422GAA5NOTE 2.250% 3/0–$7.93M0.7%–––
ELVNEnliven Therapeutics, Inc.COM400,000$8.19M0.8%00.0%UnchangedHistory
VERAVera Therapeutics, Inc.CL A303,330$8.81M0.8%−241,670−44.3%ReducedHistory
NRIXNurix Therapeutics, Inc.COM967,620$8.94M0.8%00.0%UnchangedHistory
ERASErasca, Inc.COM4,285,787$9.34M0.9%+200,000+4.9%AddedHistory
TSHATaysha Gene Therapies, Inc.COM SHS3,000,000$9.81M0.9%+2,800,000+1,400.0%AddedHistory
DNTHDianthus Therapeutics, Inc.COM262,100$10.3M1.0%+262,100NewHistory
TVTXTravere Therapeutics, Inc.COM500,000$11.9M1.1%−470,000−48.5%ReducedHistory
ROIVRoivant Sciences Ltd.SHS800,000$12.1M1.1%+400,000+100.0%AddedHistory
VTYXVentyx Biosciences, Inc.COM3,924,415$12.2M1.1%−611,767−13.5%ReducedHistory
Karyopharm Therapeutics Inc.48576UAA4NOTE 3.000%10/1–$12.5M1.2%–––
ESTAEstablishment Labs Holdings Inc.COM310,000$12.7M1.2%−24,863−7.4%ReducedHistory
AVTXAvalo Therapeutics, Inc.COM NEW1,006,217$12.8M1.2%+398,345+65.5%AddedHistory
SLNOSoleno Therapeutics IncCOM200,000$13.5M1.3%+200,000NewHistory
PTGXProtagonist Therapeutics, IncCOM220,600$14.7M1.4%−219,400−49.9%ReducedHistory
WVEWave Life Sciences, Inc.SHS2,100,000$15.4M1.4%+99,692+5.0%AddedHistory
QUREuniQure N.V.SHS300,000$17.5M1.6%+165,000+122.2%AddedHistory
ORKAOruka Therapeutics, Inc.COM959,180$18.4M1.7%+355,701+58.9%AddedHistory
CYTKCytokinetics IncCOM NEW350,000$19.2M1.8%+350,000NewHistory
RZLTRezolute, Inc.COM NEW2,100,000$19.7M1.8%−100,000−4.5%ReducedHistory
SYRESpyre Therapeutics, Inc.COM NEW1,419,299$23.8M2.2%+812,621+133.9%AddedHistory
TRVITrevi Therapeutics, Inc.COM2,800,000$25.6M2.4%+265,942+10.5%AddedHistory
LXEOLexeo Therapeutics, Inc.COM3,870,527$25.7M2.4%+281,172+7.8%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS1,107,162$26.8M2.5%+207,000+23.0%AddedHistory
MRUSMerus N.V.COM285,769$26.9M2.5%+215,769+308.2%AddedHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS1,400,000$28.3M2.6%00.0%UnchangedHistory
MLYSMineralys Therapeutics, Inc.COM750,000$28.4M2.6%−150,000−16.7%ReducedHistory
ABVXAbivax S.A.SPONSORED ADS360,000$30.6M2.8%+260,000+260.0%AddedHistory
NUVLNuvalent, Inc.COM384,417$33.2M3.1%−30,583−7.4%ReducedHistory
ALKSAlkermes plc.SHS1,250,000$37.5M3.5%+250,000+25.0%AddedHistory
ACLXArcellx, Inc.COMMON STOCK500,000$41.0M3.8%+5,000+1.0%AddedHistory
APGEApogee Therapeutics, Inc.COM1,173,426$46.6M4.3%+481,527+69.6%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM115,000$52.7M4.9%+35,000+43.8%AddedHistory
XENEXenon Pharmaceuticals Inc.COM1,400,000$56.2M5.2%+300,000+27.3%AddedHistory
SPYSPDR S&P 500 ETF TrustETF84,490$56.3M5.2%+84,490NewHistory
INSMINSMED IncCOM PAR $.01450,000$64.8M6.0%−25,000−5.3%ReducedHistory
VRNAVerona Pharma plcSPONSORED ADS625,000$66.7M6.2%+15,000+2.5%AddedHistory

Options (9)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q3 2025
SecurityClassPutsCalls
INSMINSMED IncCOM PAR $.01–$29.5M
EXELExelixis, Inc.COM$14.5M$6.20M
SMMTSummit Therapeutics Inc.COM$7.23M–
NTLAIntellia Therapeutics, Inc.COM–$5.18M
OMEROmeros CorpCOM$4.65M–
OLMAOlema Pharmaceuticals, Inc.COM–$2.45M
ATYRaTYR PHARMA INCCOM NEW$1.51M–
KPTIKaryopharm Therapeutics Inc.COM NEW–$1.03M
ABUSArbutus Biopharma CorpCOM–$960.2K

Sold out since Q2 2025 (10)

Positions held at the end of Q2 2025 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q2 2025
SecurityClassShares in Q2 2025Value in Q2 2025% of portfolio in Q2 2025History
BPMCBlueprint Medicines CorpCOM250,000$32.0M4.7%History
INZYInozyme Pharma, Inc.COM1,749,359$7.00M1.0%History
AXSMAxsome Therapeutics, Inc.COM50,000$5.22M0.8%History
RAPPRapport Therapeutics, Inc.COM199,643$2.27M0.3%History
THRDThird Harmonic Bio, Inc.COM370,000$2.01M0.3%History
NKTXNkarta, Inc.COM800,000$1.33M0.2%History
MIRMMirum Pharmaceuticals, Inc.COM24,692$1.26M0.2%History
OKUROnKure Therapeutics, Inc.COM CL A347,990$831.7K0.1%History
RADXRadiopharm Theranostics LtdSPONSORED ADS35,635$166.1K<0.1%History
Immatics N.V.N44445117*W EXP 07/01/202187,204$112<0.1%–